Last reviewed · How we verify
Loxoprofen sodium hydrogel patch
Loxoprofen sodium hydrogel patch is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by Sun Yat-sen University. It is currently FDA-approved for Localized pain and inflammation (musculoskeletal pain, arthritis), Transdermal pain relief. Also known as: Loxoprofen hydrogel patch.
Loxoprofen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.
Loxoprofen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Used for Localized pain and inflammation (musculoskeletal pain, arthritis), Transdermal pain relief.
At a glance
| Generic name | Loxoprofen sodium hydrogel patch |
|---|---|
| Also known as | Loxoprofen hydrogel patch |
| Sponsor | Sun Yat-sen University |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Pain management / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Loxoprofen sodium blocks COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. The hydrogel patch formulation provides transdermal delivery of the drug, allowing localized anti-inflammatory and analgesic effects at the site of application while potentially reducing systemic exposure compared to oral administration.
Approved indications
- Localized pain and inflammation (musculoskeletal pain, arthritis)
- Transdermal pain relief
Common side effects
- Skin irritation at application site
- Gastrointestinal upset (if systemic absorption occurs)
- Allergic contact dermatitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Loxoprofen sodium hydrogel patch CI brief — competitive landscape report
- Loxoprofen sodium hydrogel patch updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Loxoprofen sodium hydrogel patch
What is Loxoprofen sodium hydrogel patch?
How does Loxoprofen sodium hydrogel patch work?
What is Loxoprofen sodium hydrogel patch used for?
Who makes Loxoprofen sodium hydrogel patch?
Is Loxoprofen sodium hydrogel patch also known as anything else?
What drug class is Loxoprofen sodium hydrogel patch in?
What development phase is Loxoprofen sodium hydrogel patch in?
What are the side effects of Loxoprofen sodium hydrogel patch?
What does Loxoprofen sodium hydrogel patch target?
Related
- Drug class: All Nonsteroidal anti-inflammatory drug (NSAID) drugs
- Target: All drugs targeting Cyclooxygenase (COX-1 and COX-2)
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Pain management / Rheumatology
- Indication: Drugs for Localized pain and inflammation (musculoskeletal pain, arthritis)
- Indication: Drugs for Transdermal pain relief
- Also known as: Loxoprofen hydrogel patch
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing